No CrossRef data available.
Article contents
Estimating Clostridioides difficile infection-associated readmission rates: A systematic review and meta-analysis
Published online by Cambridge University Press: 27 May 2024
Abstract
Background:
The economic burden of Clostridioides difficile infection (CDI) is considerable and mostly associated with a high frequency of hospitalizations. Numerous publications have demonstrated that CDI is associated with a higher risk of hospital readmission, but not always a specific rate or attributable to disease recurrence.
Methods:
In this systematic review, we describe the incidence of 30-day CDI-associated readmission rates and the effect of active interventions. Three search engines were utilized for the literature search, and a total of 9 studies were included in this review. Hospital readmission proportions from interventional and observational studies were analyzed through meta-analysis with random effects.
Results:
Two thousand five hundred and twenty-one articles were identified. After screening full-text articles, 9 eligible articles published between 2002 and 2023 met the inclusion criteria. In total, 132,862 CDI patients were evaluated. Thirty-day CDI-associated readmissions were defined as either an ICD9/10 code indicating CDI admission with a prior admission within the past 30 days (n = 4) or a medical chart evaluation of signs and symptoms consistent with CDI (diarrhea) along with a positive diagnostic test (n = 5) with a prior hospitalization for CDI within the past 30 days. Meta-analysis of observational studies estimated 30-day CDI readmissions were 6% (95% CI, 5%–7%). Three studies evaluated the effect of active interventions to reduce CDI-associated 30-day readmission rates. Two of 3 interventions reduced the likelihood of CDI-associated 30-day readmissions.
Conclusions:
This systematic review identified a 6% rate of 30-day CDI-associated hospital readmission. Antimicrobial stewardship efforts and the use of specific therapeutics were shown to reduce these rates.
- Type
- Original Article
- Information
- Copyright
- © The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Footnotes
*
Both authors contributed equally.
References
Guh, AY, Mu, Y, Winston, LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020;382:1320–1330.CrossRefGoogle ScholarPubMed
Olsen, MA, Stwalley, D, Demont, C, Dubberke, ER.
Clostridium difficile infection increases acute and chronic morbidity and mortality. Infect Control Hosp Epidemiol 2019;40:65–71.CrossRefGoogle ScholarPubMed
Mitchell, BG, Gardner, A. Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 2012;1:20.CrossRefGoogle ScholarPubMed
Feuerstadt, P, Theriault, N, Tillotson, G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis 2023;23:132.CrossRefGoogle ScholarPubMed
Ghantoji, SS, Sail, K, Lairson, DR, DuPont, HL, Garey, KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010;74:309–318.CrossRefGoogle ScholarPubMed
Dubberke, ER, Gerding, DN, Kelly, CP, et al. Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis 2020;7:ofaa157.CrossRefGoogle ScholarPubMed
Guterman, S, Dobson, A. Impact of the Medicare prospective payment system for hospitals. Health Care Financ Rev 1986;7:97–114.Google ScholarPubMed
Shaw, JA, Stiliannoudakis, S, Qaiser, R, Layman, E, Sima, A, Ali, A. Thirty-day hospital readmissions: a predictor of higher all-cause mortality for up to two years. Cureus 2020;12:e9308.Google ScholarPubMed
Rinne, ST, Castaneda, J, Lindenauer, PK, Cleary, PD, Paz, HL, Gomez, JL. Chronic obstructive pulmonary disease readmissions and other measures of hospital quality. Am J Respir Crit Care Med 2017;196:47–55.CrossRefGoogle ScholarPubMed
Page, MJ, McKenzie, JE, Bossuyt, PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed) 2021;74:790–799.CrossRefGoogle ScholarPubMed
Lo, CK, Mertz, D, Loeb, M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 2014;14:45.CrossRefGoogle ScholarPubMed
R Core Team (2021). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/.Google Scholar
Brumley, PE, Malani, AN, Kabara, JJ, Pisani, J, Collins, CD. Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection. J Antimicrob Chemother 2016;71:836–840.CrossRefGoogle ScholarPubMed
Chopra, T, Neelakanta, A, Dombecki, C, et al. Burden of Clostridium difficile infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction Program. Am J Infect Control 2015;43:314–317.CrossRefGoogle ScholarPubMed
Collins, CE, Ayturk, MD, Anderson, FA Jr., Santry, HP. Predictors and outcomes of readmission for Clostridium difficile in a national sample of Medicare beneficiaries. J Gastrointest Surg 2015;19:88–99.CrossRefGoogle Scholar
Eiland, EH 3rd, Sawyer, AJ, Massie, NL. Fidaxomicin use and clinical outcomes for Clostridium difficile-associated diarrhea. Infect Dis Clin Pract (Baltim Md) 2015;23:32–35.CrossRefGoogle ScholarPubMed
McDaniel, LF, White, MN, Obi, EN, et al. Clinical and economic outcomes after implementation of a fidaxomicin treatment optimization and access pathway at a US hospital system. Infect Dis Ther 2023;12:95–107.CrossRefGoogle Scholar
Miller, MA, Hyland, M, Ofner-Agostini, M, Gourdeau, M, Ishak, M, Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance P. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137–140.CrossRefGoogle Scholar
Prabhu, VS, Cornely, OA, Golan, Y, et al. Thirty-day readmissions in hospitalized patients who received bezlotoxumab With antibacterial drug treatment for Clostridium difficile infection. Clin Infect Dis 2017;65:1218–1221.CrossRefGoogle ScholarPubMed
Sharma, S, Weissman, S, Walradt, T, et al. Readmission, healthcare consumption, and mortality in Clostridioides difficile infection hospitalizations: a nationwide cohort study. Int J Colorectal Dis 2021;36:2629–2635.CrossRefGoogle ScholarPubMed
Verheyen, E, Dalapathi, V, Arora, S, et al. High 30-day readmission rates associated with Clostridium difficile infection. Am J Infect Control 2019;47:922–927.CrossRefGoogle Scholar
Hengel, RL, Schroeder, CP, Jo, J, et al. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. J Patient Rep Outcomes 2022;6:49.CrossRefGoogle ScholarPubMed
Gabriel, L, Beriot-Mathiot, A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect 2014;88:12–21.CrossRefGoogle ScholarPubMed
Upadhyay, S, Stephenson, AL, Smith, DG. Readmission rates and their impact on hospital financial performance: a study of Washington hospitals. Inquiry 2019;56:46958019860386.Google ScholarPubMed
Fischer, C, Lingsma, HF, Marang-van de Mheen, PJ, Kringos, DS, Klazinga, NS, Steyerberg, EW. Is the readmission rate a valid quality indicator? A review of the evidence. PLoS One 2014;9:e112282.CrossRefGoogle Scholar